Medicines Development for Global Health’s (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

Shots:

• The approval is based on two clinical studies results assessing Moxidectin vs SoC Ivermectin in patients with river blindness aged ≥ 12 yrs.
• The study resulted in meeting 1EPswith superiority of Moxidectin vs SoC Ivermectin and resulted in suppression of microfilariae in the skin
• Moxidectin (8mg, PO) is macrocyclic lactone anthelmintic medication active against O.volvulus microfilariae and has also received FDA’s PRV on 13 Jun, 2018 with its accelerated NDA review from 10 to 6mos.

Click here to read full press release/ article | Ref: Medicines Development for Global Health | Image: CmocroI